What's new

Human medicines European public assessment report (EPAR): Kayfanda, odevixibat, Date of authorisation: 19/09/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Kayfanda, odevixibat, Date of authorisation: 19/09/2024, Revision: 1, Status: Authorised

Apr 10, 2025 - 14:08
 0
Human medicines European public assessment report (EPAR): Kayfanda, odevixibat, Date of authorisation: 19/09/2024, Revision: 1, Status: Authorised
Human medicines European public assessment report (EPAR): Kayfanda, odevixibat, Date of authorisation: 19/09/2024, Revision: 1, Status: Authorised
Read More

Tags:

Previous Article

Whiplash from Trump’s tariff pause

Next Article

Human medicines European public assessment report (EPAR): Ebglyss, Lebrikizumab,...

Related Posts

3Rs Working Party

3Rs Working Party

Feb 9, 2025  0

Human medicines European public assessment report (EPAR): Paxneury, guanfacine, Date of authorisation: 26/02/2025, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 11, 2025  0

Orphan designation: Venetoclax Treatment of diffuse large B-cell lymphoma, 14/10/2016 Withdrawn

Orphan designation: Venetoclax Treatment of diffuse lar...

Mar 11, 2025  0